Jirayos Chintanadilok
Pulmonary Disease · Marianna, FLNPI 1073516274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,308 and has fallen 81.2% since, to $247 in 2022. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 233 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$744
- Grifols USA, LLC$691
- GSK$528
- Kowa Pharmaceuticals America, Inc.$203
- Philips North America LLC$185
- Novo Nordisk$150
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,882100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 36 | $744 |
| Grifols USA, LLC | 43 | $691 |
| GSK | 46 | $528 |
| Kowa Pharmaceuticals America, Inc. | 14 | $203 |
| Philips North America LLC | 7 | $185 |
| Novo Nordisk | 7 | $150 |
| Novartis | 11 | $143 |
| AstraZeneca | 9 | $142 |
| Inari Medical, Inc. | 1 | $139 |
| Mylan Specialty L.p. | 6 | $129 |
| Lilly USA, LLC | 8 | $124 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Sunovion Pharmaceuticals Inc. | 7 | $89 |
| Jazz Pharmaceuticals Inc. | 5 | $76 |
| Amgen | 4 | $64 |
| Dexcom, Inc. | 3 | $60 |
| Electromed, Inc. | 3 | $40 |
| Pfizer | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $30 |
| Merck | 2 | $30 |
| AbbVie | 2 | $27 |
| Johnson & Johnson | 2 | $27 |
| Harmony Biosciences LLC | 1 | $26 |
| Gilead | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Bayer | 1 | $17 |
| Strongbridge US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,898 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $6,794 |
| Divalproex Sodium | 11 | $989 |
| ClopidogrelClopidogrel Bisulfate | 25 | $449 |
| Atorvastatin Calcium | 21 | $324 |
| Gabapentin | 11 | $305 |
| Potassium Chloride | 13 | $291 |
| Losartan Potassium | 12 | $256 |
| Amlodipine Besylate | 12 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $6,79423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Marianna
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.